Replimune Group, Inc.
For the period ended Mar 31, 2025. Filed May 22, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed May 22, 2025
REPL$23.28+4.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of stockholders’ equity F-
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Amounts in thousands, except share amounts)
| Common stock · Additional paid-in capital · Accumulated deficit · Accumulated other comprehensive income · Total stockholders’ equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balances as of March 31, 2023 | 56,676,313 | $57 | $1,034,994 | $(485,488) | $5,729 | $555,292 |
| Foreign currency translation adjustment | — | — | — | — | (826) | (826) |
| Unrealized gain on short-term investments | — | — | — | — | (48) | (48) |
| Exercise of pre-funded warrants | 4,202,622 | 4 | (4) | — | — | — |
| Exercise of stock options | 164,221 | — | 1,759 | — | — | 1,759 |
| Vesting of RSUs | 371,949 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 34,125 | — | — | 34,125 |
| Net loss | — | — | — | (215,794) | — | (215,794) |
| Balances as of March 31, 2024 | 61,415,105 | $61 | $1,070,874 | $(701,282) | $4,855 | $374,508 |
| Issuance of prefunded warrants to purchase common stock, net of issuance costs | — | — | 97,000 | — | — | 97,000 |
| Issuance of common stock, net of issuance costs and underwriter fees | 14,207,314 | 14 | 155,714 | — | — | 155,728 |
| Foreign currency translation adjustment | — | — | — | — | 174 | 174 |
| Unrealized gain on short-term investments | — | — | — | — | 419 | 419 |
| Exercise of pre-funded warrants | 739,225 | 1 | (1) | — | — | — |
| Exercise of stock options | 84,261 | — | 267 | — | — | 267 |
| Vesting of RSUs | 639,119 | 1 | (1) | — | — | — |
| Stock-based compensation expense | — | — | 35,044 | — | — | 35,044 |
| Net loss | — | — | — | (247,297) | — | (247,297) |
| Balances as of March 31, 2025 | 77,085,024 | $77 | $1,358,897 | $(948,579) | $5,448 | $415,843 |
F - 7
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.